Friday, June 29, 2007 6:51:26 AM
As you predicted, it ain't over yet:
Generic Pharmaceutical Association hires Greenberg Traurig to lobby federal government -- June 28, 2007
http://www.sddt.com/Search/SearchResults.cfm?Expression=The+Generic
WASHINGTON (AP) -- The Generic Pharmaceutical Association hired Greenberg Traurig LLP to lobby the federal government, according to a disclosure form. The firm will represent the industry on international trade issues, according to the form filed Wednesday. On its Web site, the Arlington, Va.-based trade group said it is concerned about intellectual property provisions in recent free trade agreements that could block generic drug exports to other countries and hamper competition for generic drugs in the United States.
Regina K. Vargo, who was assistant U.S. Trade Representative for the Americas from 2001 to 2006, and James Bacchus, a former U.S. representative from Florida and former chairman of the WTO's Appellate Body, are among those registered to lobby on behalf of the trade group.
The group's membership includes companies, such as Hospira Inc., Mylan Laboratories Inc. and Watson Pharmaceuticals Inc.
Under a federal law enacted in 1995, lobbyists are required to disclose activities that could influence members of the executive and legislative branches. They must register with Congress within 45 days of being hired or engaging in lobbying.
Generic Pharmaceutical Association hires Greenberg Traurig to lobby federal government -- June 28, 2007
http://www.sddt.com/Search/SearchResults.cfm?Expression=The+Generic
WASHINGTON (AP) -- The Generic Pharmaceutical Association hired Greenberg Traurig LLP to lobby the federal government, according to a disclosure form. The firm will represent the industry on international trade issues, according to the form filed Wednesday. On its Web site, the Arlington, Va.-based trade group said it is concerned about intellectual property provisions in recent free trade agreements that could block generic drug exports to other countries and hamper competition for generic drugs in the United States.
Regina K. Vargo, who was assistant U.S. Trade Representative for the Americas from 2001 to 2006, and James Bacchus, a former U.S. representative from Florida and former chairman of the WTO's Appellate Body, are among those registered to lobby on behalf of the trade group.
The group's membership includes companies, such as Hospira Inc., Mylan Laboratories Inc. and Watson Pharmaceuticals Inc.
Under a federal law enacted in 1995, lobbyists are required to disclose activities that could influence members of the executive and legislative branches. They must register with Congress within 45 days of being hired or engaging in lobbying.
Recent TEVA News
- The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults • GlobeNewswire Inc. • 05/21/2026 04:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:02:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:00:48 PM
- Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution • GlobeNewswire Inc. • 05/18/2026 12:30:00 PM
- Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact • GlobeNewswire Inc. • 05/18/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 08:02:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 07:59:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 08:01:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 08:00:07 PM
- Teva to Present at the BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/04/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:02:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 08:00:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 12:12:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/30/2026 08:40:45 PM
- Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 08:06:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:00:20 AM
- Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy • GlobeNewswire Inc. • 04/29/2026 10:30:00 AM
- Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 08:43:03 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/31/2026 08:41:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/31/2026 08:38:29 PM
